Earnings Meet Expectations as Cabaletta Bio Navigates Clinical Hurdles Cabaletta Bio reported a Q4 2024 loss of $0.65 per share, aligning with consensus forecasts. Recent trial safety concerns, including a Grade 3 neurotoxicity event, prompted protocol adjustments. Despite a steep share price drop, analysts largely maintain Buy ratings, reflecting confidence in the company’s long-term prospects.456